Sacubitril-Valsartan

ApprovedSmall molecule

FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Sacubitril-Valsartan is one of 141 small molecule programs targeting Myocardial fibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial FibrosisActive, not recruiting

Myocardial InfarctionActive, not recruiting

CardiotoxicityActive, not recruiting

HypertensionActive, not recruiting

Heart FailureActive, not recruiting

Atrial FibrillationActive, not recruiting

Takotsubo CardiomyopathyActive, not recruiting

Myocardial FibrosisApproved

Active, not recruiting

Myocardial InfarctionPhase 3

Active, not recruiting

CardiotoxicityApproved

Active, not recruiting

HypertensionPhase 2

Active, not recruiting

Heart FailurePhase 3

Active, not recruiting

Atrial FibrillationApproved

Active, not recruiting

Takotsubo CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Sacubitril-Valsartan

FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Approved

15 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Monoferric

PPharmacosmos A/S

Preclinical

5 6

Activase

Roche

Preclinical

—7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 8

Xifaxan

SSalix

Preclinical

2 9

Zoloft

VViatris Specialty LLC

Preclinical

2 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Hemodialysis

NCT05498181

Q1 2027

Phase 2/3Recruiting

Study completion

NCT04971720

Q2 2027

Phase 3Recruiting

Heart Failure

NCT05508035

Phase 3Not yet recruiting

Heart Failure

NCT06712030

Q3 2028

N/ARecruiting

Takotsubo Cardiomyopathy

NCT07491718

Clinical

Trials by Indication[1]

Heart Failure15 trials

Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan

Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla··NCT04185103·20 enrolled

Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure

Completed·CCentro Cardiologico Monzino··NCT04434170·112 enrolled

The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction

Recruiting·JJohn Paul II Hospital, Krakow·Phase 3·NCT05508035·666 enrolled

Show 12 more trials

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

Completed·—·Phase 4·NCT04575675·78 enrolled

Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

Withdrawn·FFlinders University·Phase 3·NCT04128891

Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction

Unknown status·SSamsung Medical Center··NCT04803175·100 enrolled

The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure

Completed·AAmir Safwat·Phase 4·NCT04688294·60 enrolled

Influence of Sacubitril/Valsartan on Autonomic Cardiac Nervous System in Heart Failure Patients: an Exploratory Study

Completed·—·N/A·NCT04587947·63 enrolled

Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure

Unknown status·UUniversity of Leipzig··NCT04498780·117 enrolled

Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction

Not yet recruiting·PPuerta de Hierro University Hospital·Phase 3·NCT06712030·114 enrolled

Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

Completed·NNational Heart Institute, Egypt·Phase 2/3·NCT07023016·515 enrolled

Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction

Unknown status·—·Phase 4·NCT05487261·260 enrolled

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

Active, not recruiting·ZZiekenhuis Oost-Limburg·Phase 4·NCT05991284·84 enrolled

Sacubitril-valsartan in Patients With Heart Failure.

Recruiting·—·N/A·NCT07341893·60 enrolled

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Recruiting·VVirginia Commonwealth University·Preclinical·NCT05194111·70 enrolled

Hypertension1 trial

Sacubitril/Valsartan in Resistant Hypertension

Completed·HHospital Geral Roberto Santos·Phase 2·NCT04637152·80 enrolled

Cardiac Failure1 trial

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Recruiting·KKhawaja Danish Ali·Phase 1·NCT07444398·130 enrolled

TIA1 trial

Initiation of ARNi and SGLT2i in Patients With HFrEF

Completed·UUniversidade do Porto·Phase 4·NCT05989503·62 enrolled

Cardiac1 trial

Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output

Withdrawn·TThe Cleveland Clinic·Phase 4·NCT04206865

14 more indications

Chronic1 trial

Open Label RCT for Chronic Severe AR : Entresto vs. CCB/ARB

Unknown status·SSamsung Medical Center·Phase 2·NCT05212597·100 enrolled

Not yet recruiting·WWest China Hospital·Phase 3·NCT04912167·376 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

Recruiting·TThe Cleveland Clinic·Phase 4·NCT04191681·50 enrolled

Myocardial fibrosis1 trial

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

Not yet recruiting·—·Phase 4·NCT06536309·36 enrolled

Dialysis Patients1 trial

The Effect of Sacubitril and Valsartan on Heart Function in Chronic Hemodialysis Patients With HFpEF

Not yet recruiting·—·Phase 4·NCT07417215·60 enrolled

Hemodialysis1 trial

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

Recruiting·—·Phase 2·NCT05498181·100 enrolled

Observational Study1 trial

Prospective Observational Study of the Sacubitril-Valsartan Treatment Effectiveness.

Unknown status·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla··NCT04133428·100 enrolled

Takotsubo cardiomyopathy1 trial

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Recruiting·UUniversity of Edinburgh·N/A·NCT07491718·100 enrolled

Prospective1 trial

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

Unknown status·MMark Ledwidge·Phase 2·NCT04687111·250 enrolled

ALS1 trial

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients

Active, not recruiting·UUniversity of Zagreb·Phase 4·NCT04103554·60 enrolled

Cardiotoxicity1 trial

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Recruiting·SSilesian Centre for Heart Diseases·Phase 4·NCT05465031·600 enrolled

Unspecified1 trial

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

Recruiting·UUniversity of Alabama at Birmingham·Phase 2/3·NCT04971720·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Sacubitril-Valsartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sacubitril-Valsartan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sacubitril-Valsartan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFundación Pública Andaluza para la gestión de la Investigación en Sevilla

Sacubitril-Valsartan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Q2 2027

Q3 2028

Trials by Indication[1]

Heart Failure15 trials

Hypertension1 trial

Cardiac Failure1 trial

TIA1 trial

Cardiac1 trial

Chronic1 trial

Atrial Fibrillation1 trial

Catheter Ablation1 trial

Myocardial Infarction1 trial

Safety and Efficacy1 trial

Myocardial fibrosis1 trial

Dialysis Patients1 trial

Hemodialysis1 trial

Observational Study1 trial

Takotsubo cardiomyopathy1 trial

Prospective1 trial

ALS1 trial

Cardiotoxicity1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News